MA44783A - Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4 - Google Patents

Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4

Info

Publication number
MA44783A
MA44783A MA044783A MA44783A MA44783A MA 44783 A MA44783 A MA 44783A MA 044783 A MA044783 A MA 044783A MA 44783 A MA44783 A MA 44783A MA 44783 A MA44783 A MA 44783A
Authority
MA
Morocco
Prior art keywords
ctla
antibody
formulation
compositions containing
compositions
Prior art date
Application number
MA044783A
Other languages
English (en)
Inventor
Jiali Du
Ambarish Shah
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA44783A publication Critical patent/MA44783A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044783A 2016-04-25 2017-04-24 Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4 MA44783A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662327214P 2016-04-25 2016-04-25

Publications (1)

Publication Number Publication Date
MA44783A true MA44783A (fr) 2019-03-06

Family

ID=60089975

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044783A MA44783A (fr) 2016-04-25 2017-04-24 Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4

Country Status (19)

Country Link
US (2) US10421811B2 (fr)
EP (1) EP3448428A4 (fr)
JP (1) JP2019514889A (fr)
KR (1) KR20180135475A (fr)
CN (1) CN109069631A (fr)
AR (1) AR108317A1 (fr)
AU (1) AU2017257505B2 (fr)
BR (1) BR112018071287A2 (fr)
CA (1) CA3020893A1 (fr)
CL (1) CL2018002998A1 (fr)
CO (1) CO2018011195A2 (fr)
IL (1) IL262344A (fr)
MA (1) MA44783A (fr)
MX (1) MX2018012651A (fr)
RU (1) RU2018140960A (fr)
SG (1) SG11201807474SA (fr)
TW (1) TW201740976A (fr)
WO (1) WO2017189433A1 (fr)
ZA (1) ZA201807888B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019344B1 (ru) * 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
PL3043816T3 (pl) * 2013-09-11 2020-03-31 Medimmune Limited Przeciwciała anty-b7-h1 do leczenia nowotworów
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
DK3099717T3 (da) 2014-01-31 2019-07-01 Novartis Ag Antistofmolekyler med tim-3 og anvendelser deraf
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
ES2749098T3 (es) * 2014-05-13 2020-03-19 Medimmune Ltd Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico
EP3191126B1 (fr) 2014-09-13 2020-05-13 Novartis AG Thérapies combinées d'inhibiteurs d'alk
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
JP6730466B2 (ja) 2016-06-13 2020-07-29 アイ−エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ−ｌ１抗体およびその使用
AU2018221822A1 (en) * 2017-02-16 2019-09-26 Medimmune, Llc Anti-PD-L1 antibody treatment of bladder cancer
US20200354453A1 (en) * 2017-05-02 2020-11-12 Merck Sharp & Dohme Corp. Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2018220446A1 (fr) 2017-06-01 2018-12-06 Compugen Ltd. Thérapies à base d'anticorps à triple combinaison
SG11202010324TA (en) * 2018-04-25 2020-11-27 Medimmune Ltd Formulations of human anti-pd-l1 antibodies
WO2020020307A1 (fr) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anticorps bispécifiques anti-cd73 anti-pd-l1
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
JP2024505128A (ja) * 2020-12-30 2024-02-05 アイ－エムエービー バイオファーマ カンパニー リミテッド 抗ｃｄ７３抗体の製剤
AR130954A1 (es) * 2022-11-04 2025-02-05 Astrazeneca Ab Composiciones de anticuerpo anti-ctla y métodos relacionados

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096461A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps contre m-csf
CA2647282A1 (fr) * 2006-04-05 2007-10-11 Pfizer Products Inc. Polytherapie a base d'un anticorps anti-ctla4
HUE065752T2 (hu) * 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2504364T (pt) * 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
CN107496917B (zh) * 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
JP2015502397A (ja) * 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
ES2749098T3 (es) * 2014-05-13 2020-03-19 Medimmune Ltd Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico
WO2016030455A1 (fr) * 2014-08-28 2016-03-03 Medimmune Limited Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules
CN115920007A (zh) * 2014-10-24 2023-04-07 阿斯利康(瑞典)有限公司 组合
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia

Also Published As

Publication number Publication date
EP3448428A4 (fr) 2019-11-27
RU2018140960A (ru) 2020-05-26
WO2017189433A1 (fr) 2017-11-02
MX2018012651A (es) 2019-01-30
AU2017257505A1 (en) 2018-12-06
US10421811B2 (en) 2019-09-24
CL2018002998A1 (es) 2018-12-07
TW201740976A (zh) 2017-12-01
AR108317A1 (es) 2018-08-08
AU2017257505B2 (en) 2020-05-14
CO2018011195A2 (es) 2018-10-31
IL262344A (en) 2018-11-29
CA3020893A1 (fr) 2017-11-02
KR20180135475A (ko) 2018-12-20
US20170306025A1 (en) 2017-10-26
ZA201807888B (en) 2019-08-28
BR112018071287A2 (pt) 2019-02-19
US20190382494A1 (en) 2019-12-19
CN109069631A (zh) 2018-12-21
EP3448428A1 (fr) 2019-03-06
JP2019514889A (ja) 2019-06-06
RU2018140960A3 (fr) 2020-08-03
SG11201807474SA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MA44783A (fr) Compositions comprenant une co-formulation d'anticorps anti-pd-l1 et anti-ctla-4
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
PL3882275T3 (pl) Przeciwciało dwufunkcyjne anty-pd-1 i anty-vegfa, kompozycja farmaceutyczna i zastosowanie tych przeciwciał
EP3505535A4 (fr) Anticorps monoclonal anti-pd-1, composition pharmaceutique et utilisation de celui-ci
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA49043A (fr) Formulation stable d'anticorps
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
EP3511346A4 (fr) Anticorps bifonctionnel anti-ctla4 et anti-pd -1, composition pharmaceutique et utilisation associées
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
DK3541841T3 (da) Anti-PD-1-antistoffer og sammensætninger
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA71409A (fr) Constructions d'anticorps pour dll3 et cd3
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
EP3383914A4 (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3589648A4 (fr) Formulation d'anticorps monoclonal anti-rsv
EP3589660A4 (fr) Anticorps anti-pd-l1 et utilisations associées
EP3773718A4 (fr) Compositions et procédés comprenant des anticorps anti-nrp2
MA44054A (fr) Plateforme d'anticorps bispécifique